Aldosterone-synthase overexpression in heart: a tool to explore aldosterone’s effects

Beggah, 2002, Reversible cardiac fibrosis and heart failure induced by conditional expression of an antisense mRNA of the mineralocorticoid receptor in cardiomyocytes, Proc. Natl. Acad. Sci. U.S.A., 99, 7160, 10.1073/pnas.102673599

Benetos, 1997, Pulse pressure, a predictor of long-term cardiovascular mortality in a French male population, Hypertension, 30, 1410, 10.1161/01.HYP.30.6.1410

Benitah, 1999, Aldosterone upregulates Ca(2+) current in adult rat cardiomyocytes, Circ. Res., 85, 1139, 10.1161/01.RES.85.12.1139

Benitah, 2001, Effects of aldosterone on transient outward K+ current density in rat ventricular myocytes, J. Physiol., 537, 151, 10.1111/j.1469-7793.2001.0151k.x

Bhargava, 2001, The serum- and glucocorticoid-induced kinase is a physiological mediator of aldosterone action, Endocrinology, 142, 1587, 10.1210/en.142.4.1587

Bonvalet, 1990, Distribution of 11-beta-hydroxysteroid-deshydrogenase along the rabbit nephron, J. Clin. Invest., 86, 832, 10.1172/JCI114781

Brilla, 1993, Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism, J. Mol. Cell. Cardiol., l25, 563, 10.1006/jmcc.1993.1066

Casal, 2003, Expression and modulation of the steroidogenic acute regulatory (StAR) protein mRNA in rat cardiocytes and after myocardial infarction, Endocrinology, 144, 1861, 10.1210/en.2002-220943

Farman, 2001, Multiple aspects of mineralocorticoid selectivity, Am. J. Physiol. Renal Physiol., 280, F181, 10.1152/ajprenal.2001.280.2.F181

Farquharson, 2000, Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure, Circulation, 101, 594, 10.1161/01.CIR.101.6.594

Francis, 2003, Central mineralocorticoid receptor blockade decreases plasma TNF-alpha after coronary artery ligation in rats, Am. J. Physiol. Regul. Integr. Comp. Physiol., 284, R328, 10.1152/ajpregu.00376.2002

Funder, 1997, Glucocorticoid and mineralocorticoid receptors. Biology and clinical relevance, Ann. Rev. Med., 448, 231, 10.1146/annurev.med.48.1.231

Funder, 1988, Mineralocorticoid action, target tissue specificity is enzyme, not receptor, mediated, Science, 242, 583, 10.1126/science.2845584

Gomez-Sanchez, 1997, Aldosterone biosynthesis in the rat brain, Endocrinology, 138, 3369, 10.1210/en.138.8.3369

Harada, 2001, Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes, Circulation, 104, 137, 10.1161/01.CIR.104.2.137

Lacolley, 2001, Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats, J. Am. Coll. Cardiol., 37, 662, 10.1016/S0735-1097(00)01129-3

Lacolley, 2002, Increased carotid wall elastic modulus and fibronectin in aldosterone–salt treated rats. Effects of eplerenone, Circulation, 106, 2848, 10.1161/01.CIR.0000039328.33137.6C

Lombès, 1994, The mineralocorticoid receptor discriminates aldosterone from glucocorticoids independently of the 11-beta-hydroxysteroid dehydrogenase, Endocrinology, 135, 834, 10.1210/en.135.3.834

Lombès, 1995, Prerequiste for cardiac aldosterone action. Mineralocorticoid receptor and 11-beta-hydroxysteroid dehydrogenase in the human heart, Circulation, 92, 175, 10.1161/01.CIR.92.2.175

Mizuno, 2001, Aldosterone production is activated in failing ventricle in humans, Circulation, 103, 72, 10.1161/01.CIR.103.1.72

Park, 2002, Cardiac and vascular fibrosis and hypertrophy in aldosterone-infused rats, role of endothelin-1, Am. J. Hypertens., 15, 164, 10.1016/S0895-7061(01)02291-9

Pitt, 2003, Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction, N. Engl. J. Med., 348, 1309, 10.1056/NEJMoa030207

Pitt, 1999, The effect of spironolactone on morbidity and mortality in patients with severe heart failure, N. Engl. J. Med., 341, 709, 10.1056/NEJM199909023411001

Pitt, 1995, “Escape” of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor, implications for therapy, Cardiovasc. Drugs Ther., 9, 145, 10.1007/BF00877755

Ramires, 2000, Effect of spironolactone on ventricular arrythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy, Am. J. Cardiol., 85, 1207, 10.1016/S0002-9149(00)00729-3

Robert, 1995, Biological determinants of aldosterone-induced cardiac fibrosis in rats, Hypertension, 26, 971, 10.1161/01.HYP.26.6.971

Robert, 1999, Angiotensin AT1 receptor subtype as a cardiac target of aldosterone, role in aldosterone–salt-induced fibrosis, Hypertension, 33, 981, 10.1161/01.HYP.33.4.981

Rocha, 2002, The pathophysiology of aldosterone in the cardiovascular system, Ann. NY Acad. Sci., 970, 89, 10.1111/j.1749-6632.2002.tb04415.x

Rocha, 2002, Aldosterone induces a vascular inflammatory phenotype in the rat heart, Am. J. Physiol. Heart Circ. Physiol., 283, H1802, 10.1152/ajpheart.01096.2001

Satoh, 2002, Aldosterone synthase (CYP11B2) expression and myocardial fibrosis in the failing human heart, Clin. Sci. (Lond.), 102, 381, 10.1042/CS20010219

Silvestre, 1998, Myocardial production of aldosterone and corticosterone in the rat. Physiological regulations, J. Biol. Chem., 273, 4883, 10.1074/jbc.273.9.4883

Silvestre, 1999, Activation of cardiac aldosterone production in rat myocardial infarction. Effect of angiotensin II receptor blockade and role in cardiac fibrosis, Circulation, 99, 2694, 10.1161/01.CIR.99.20.2694

Slight, 1996, High affinity NAD+-dependent 11-beta-hydroxysteroid dehydrogenase in the human heart, J. Mol. Cell. Cardiol., 28, 781, 10.1006/jmcc.1996.0072

Sun, 1993, Ang II and aldosterone receptor binding in rat heart and kidney, response to chronic angiotensin II or aldosterone, J. Lab. Clin. Med., 122, 404

Sun, 1997, Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion, Cardiovasc. Res., 35, 138, 10.1016/S0008-6363(97)00097-7

Sun, 2002, Aldosterone-induced infalmmation in the rat heart, Am. J. Pathol., 161, 1773, 10.1016/S0002-9440(10)64454-9

Takeda, 1997, Vascular aldosterone in genetically hypertensive rats, Hypertension, 29, 45, 10.1161/01.HYP.29.1.45

Takeda, 2000, Sodium-induced cardiac aldosterone synthesis causes cardiac hypertrophy, Endocrinology, 141, 1901, 10.1210/en.141.5.1901

Trapp, 1996, Heterodimerization between mineralocorticoid and glucocorticoid receptors increases the functional diversity of corticosteroid action, Trends Pharm. Sci., 17, 145, 10.1016/0165-6147(96)81590-2

Virdis, 2002, Spironolactone improves angiotensin-induced vascular changes and oxidative stress, Hypertension, 40, 504, 10.1161/01.HYP.0000034738.79310.06

Weber, 2001, Aldosterone in congestive heart failure, N. Engl. J. Med., 345, 1689, 10.1056/NEJMra000050

Yee, 2001, Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure, J. Am. Coll. Cardiol., 37, 1800, 10.1016/S0735-1097(01)01243-8

Yoshimura, 2002, Expression of aldosterone synthase gene in failing human heart, quantitative analysis using modified real-time polymerase chain reaction, J. Clin. Endocrinol. Metab., 87, 3936, 10.1210/jc.87.8.3936

Young, 2003, Early inflammatory responses in experimental cardiac hypertrophy and fibrosis, effects of 11 beta-hydroxysteroid dehydrogenase inactivation, Endocrinology, 144, 1121, 10.1210/en.2002-220926

Zannad, 2000, Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure, insights from the randomized aldactone evaluation study (RALES), Circulation, 102, 2700, 10.1161/01.CIR.102.22.2700